Article
Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer.
Molecular cancer therapeutics - 1 Oct 2013
Li Rui, Hu Zhongliang, Sun Shi-Yong, Chen Zhuo G, Owonikoko Taofeek K, Sica Gabriel L, Ramalingam Suresh S, Curran Walter J, Khuri Fadlo R, Deng Xingming
Abstract excerpt
The emergence of resistance to EGF receptor (EGFR) inhibitor therapy is a major clinical problem for patients with non-small cell lung cancer (NSCLC). The mechanisms underlying tumor resistance to inhibitors of the kinase activity of EGFR are not fully understood. Here, we found that inhibition of EGFR by erlotinib induces STAT3 phosphorylation at Tyr705 in association with increased Bcl2/Bcl-XL at both mRNA and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.